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Abstract
The COVID-19 pandemic has stressed patients and healthcare givers alike and challenged our practice of antenatal
care, including fetal diagnosis and therapy. This document
aims to review relevant recent information to allow us to optimize prenatal care delivery. We discuss potential modifications to obstetric management and fetal procedures in
SARS-CoV2-negative and SARS-CoV2-positive patients with
fetal anomalies or disorders. Most fetal therapies are time
sensitive and cannot be delayed. If personnel and resources
are available, we should continue to offer procedures of
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proven benefit, acknowledging any fetal and maternal risks,
including those to health care workers. There is, to date, minimal, unconfirmed evidence of spontaneous vertical transmission, though it may theoretically be increased with some
procedures. Knowing a mother’s preoperative SARS-CoV-2
status would enable us to avoid or defer certain procedures
while she is contagious and to protect health care workers
appropriately. Some fetal conditions may alternatively be
managed neonatally. Counseling regarding fetal interventions which have a possibility of additional intra- or postoperative morbidity must be performed in the context of local
resource availability. Procedures of unproven benefit should
not be offered. We encourage participation in registries and
trials that may help us to understand the impact of COVID-19
on pregnant women, their fetuses, and neonates.
© 2020 S. Karger AG, Basel
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Introduction

The COVID-19 pandemic, caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2), has
altered our delivery of medical care globally. Patient mobility is limited, health care services are overwhelmed,
medical personnel are reallocated, and resources are depleted, leading to rapidly changing policies and management strategies. One consequence is an alteration in the
care of pregnant women and their fetuses. Modification
and downscaling of such care poses the risk of diagnostic
and therapeutic fetal procedures being deferred and/or
their use being queried [1–3]. Therefore, pregnant women may, in addition to their concerns about COVID-19,
be anxious about not receiving optimal antenatal care.
For some fetal conditions, this may mean that not all interventional options remain available.
The International Fetal Medicine and Surgery Society (IFMSS) wishes to complement the guidelines from
authorities and professional organizations, specifically
those pertaining to fetal medicine, while reconciling the
fetal-maternal perspectives, healthcare workers’ (HCW)
health, and public interest. We aim to provide a comprehensive overview, acknowledging that this may quickly
become outdated. The scientific knowledge and impact of
this pandemic change daily. Any guidelines should therefore be reconciled with those from authorities in infectious disease, pediatric surgery, anesthesia and transfusion, critical care, and maternal-fetal medicine.
Fetal Diagnosis and Prenatal Screening in the
COVID-19 Era

During this pandemic, individual preference should
be weighed against the greater societal good. To ensure
that our healthcare system is not overwhelmed, we should
consider segregating teams by practice location, timing,
and expertise [4]; nonessential services should be deferred or delayed and we must minimize contact between
individual patients and HCW.
Several guidelines on amended care in pregnancy care,
labor, and delivery in the COVID-19 era have already
been published [1–10]. Antenatal visits can be spaced out
[10] and telemedicine [11] and home-based care should
be utilized whenever possible [6, 7, 10]. The first antenatal
visit can be virtual, following a home pregnancy test, to
identify risk factors that may be evident in the first trimester. Counselling for Down syndrome screening can be
performed and consent obtained virtually. A 12- to 132
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week ultrasound (US) can be used to date the pregnancy,
confirm viability, screen for multiples and chronicity, exclude major structural abnormalities, and assess nuchal
translucency and, simultaneously, blood can be drawn for
routine antenatal, biochemical, or noninvasive prenatal
screening. Follow-up visits to discuss results can be virtual. Anatomical US should be delayed until 20–22 weeks
to optimize their accurate completion.
Antenatal Care for Women with SARS-CoV-2
Infection

Some patients whose fetus has an anomaly or disorder
will also have SARS-CoV-2 infection of varying severity.
The effects of this infection on mothers and fetuses are
currently unknown, and the effect of pregnancy on the
clinical course of COVID-19 disease has not been accurately characterized [4]. It seems that pregnant women
are not more prone to developing COVID-19, and their
disease course is not worse. In up to 9% of pregnancies,
the condition could be severe, but in >90% it will be mild
[12–17]. Symptoms include pyrexia, sore throat, cough,
anosmia, dyspnea, myalgia, and/or malaise, and more severe presentations range from pneumonia to acute respiratory distress syndrome and multiorgan failure [13, 14].
Presentations in pregnancy may be atypical, such as an
absence of fever or leucocytosis [15]. When complications occur, these are predominantly preterm birth, preterm prelabour rupture of membranes, preeclampsia, cesarean delivery, and possibly intensive care unit (ICU)
admission for ventilation or extracorporeal membrane
oxygenation [18].
In the case of pregnant women testing positive for
SARS-CoV-2 or COVID-19 disease, one would intuitively intensify maternal and fetal surveillance, but the potential benefits of such measures need to be balanced against
the risks of viral transmission to HCW and other patients
and the increased burden on already overstretched healthcare services.
− For asymptomatic or mildly symptomatic SARS-CoV2-positive women, most fetal screening can safely be
postponed until the infection has resolved. Asymptomatic [19] and presymptomatic [20] carriers can infect others, but their period of contagion is unknown
[21, 22]. In most places a 14-day isolation period and
being asymptomatic are used as guidelines. If the window of opportunity for US screening for trisomy 21
has passed, noninvasive prenatal screening is a reasonable alternative.
Deprest et al.

− SARS-CoV-2 infection in pregnancy may increase the
risk of preterm birth or fetal growth restriction [4].
Therefore, some recommend US monitoring at 4-week
intervals for growth, amniotic ﬂuid volume, and umbilical artery Doppler as indicated [2, 4]. In medical
or obstetric emergencies, appropriate intervention
should be based on clinical expediency.
− The care of symptomatic COVID-19 pregnant women
should be tailored to their specific symptoms with
multidisciplinary input. Fetal wellbeing should be
evaluated, as maternal respiratory insufficiency can
lead to fetal compromise. Whenever possible, vaginal
delivery is favoured to avoid unnecessary surgical
complications in an already sick patient. Caesarean delivery should be performed based on standard obstetric indications, in cases of septic shock or acute organ
failure, or to facilitate maternal ventilation or resuscitation, as this may improve the maternal condition [1,
2, 18]. Potential side effects of corticosteroids for fetal
lung maturity in COVID-19 infection have been debated, partly based on observations that glucocorticoids increase viral replication in certain circumstances [23]. Corticosteroids should therefore not be used
in asymptomatic SARS-CoV-2-positive patients or
those with mild COVID-19 symptoms, unless preterm
birth < 34 + 0 weeks’ gestation is anticipated [2, 24].
Their use in ICU patients should be judiciously evaluated, as well as in patients at >34 + 0 weeks’ gestation
[25].
There is currently little evidence of spontaneous vertical fetal transmission of SARS-CoV-2. This is somewhat
counterintuitive given that the angiotensin-converting
enzyme 2 viral receptor is widely expressed in the placenta [26, 27]. One possible explanation is that the placenta does not express transmembrane serine protease
TMPRSS2, which also plays a role in cell entry for the
SARS-CoV-2 virus, yet this is hypothetical [28, 29]. We
are unaware of documented, spontaneous vertical transmission, though limited numbers have been reported to
date [13, 30, 31]. In most cases, mothers infected in the
third trimester deliver rapidly after symptom onset, thereby limiting the potential for in utero transmission. There
are no reports (yet) of virus found in amniotic fluid or cord
blood [13]. It is too early to determine whether spontaneous viral transmission earlier in pregnancy is more likely
and/or has more adverse effects, but COVID-19 pregnancy
outcome registries should help to clarify this. IgM antibodies were detected shortly after birth in the serum of 3 symptomatic neonates [32, 33], suggesting viral exposure in utero, but IgM-based assays can be falsely positive [34].
IFMSS Guidance on Fetal Diagnosis and
Therapy during the COVID-19 Pandemic

Fetal Procedures in COVID-19 Times

Most fetal therapies are time sensitive, and delaying
them may worsen fetal, neonatal, and even maternal outcomes [35–38]. Fetal therapy should therefore not be defined as “elective.” Its provision should be guided by institutional policies and practices in the context of local
resource availability. We present 3 considerations regarding fetal interventions with SARS-CoV-2 infection.
Risk of Vertical Transmission during Fetal Procedures
Any invasive procedure in a SARS-CoV-2-positive
woman theoretically poses a risk of vertical transmission
similar to that observed in HIV-positive women prior to
effective antiviral therapy being available. There is no
confirmed evidence that such vertical transmission occurs with COVID-19, so minimally invasive procedures
(e.g., amniocentesis or fetoscopy) should continue to be
offered, ideally avoiding transplacental passage, which increases the risk of intra-amniotic bleeding and disrupts
the feto-maternal barrier. Similarly, amniocentesis may
be preferable to chorionic villus sampling (Table 1). With
open fetal surgery, the risk of maternal-fetal transmission
is likely higher than that with needle or fetoscopic procedures as the fetus is exposed to maternal blood and its skin
integrity is breached. We recommend postponing such
interventions until maternal viral clearance has been documented.
Maternal Considerations
SARS-CoV-2-negative patients in whom fetal interventions are planned should be informed that additional
assessments, hospital visits, and travel will increase their
exposure to HCW and other patients and might increase
their risk of infection. For international travel, additional
restrictions may apply, and patients may find themselves
temporarily “trapped” abroad. Patients should also be
aware that COVID-19 infection might compromise their
pregnancy outcome [4].
The risk of an asymptomatic SARS-CoV-2-positive
pregnant woman progressing to mild or severe CO
VID-19 disease is unknown, but is usually thought to be
equivalent to that of health- and age-matched women [10,
39]. Nevertheless, pregnancy’s physiological changes may
predispose to cardiorespiratory instability [4]. To avoid
the coincidence of iatrogenic surgical morbidity with additional infection related-problems, it may be prudent –
fetal condition allowing – to delay interventions until maternal infection has cleared. Typically, this is said to be
around 2–3 weeks in asymptomatic women, though a
Fetal Diagn Ther
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Table 1. Diagnostic and therapeutic procedures, estimated risks and benefits, and position based on the current knowledge and available
resources
Procedure

Benefit to
the fetus/
mother

Theoretical risk
of vertical
transmission

Risk to
healthcare
provider

Maternal
ICU need

Resource
utilization

Recommendation

Chorionic villus sampling

high

moderate

low

unlikely

minimal

offer to screen negative patients; delay to
amniocentesis in symptomatic and screen
positive patients

Amniocentesis

high

low

low

unlikely

minimal

offer to asymptomatic patients; others:
consider delay if possible

Fetal blood transfusion

high

moderate

low

unlikely

moderate

offer to screen negative patients; adjust for
symptomatic patients or screen positive
patients if it cannot be delayed

Fetal cardiac procedures

unknown

moderate

low

unlikely

moderate

consider not offering

Thoraco-amniotic shunting

high

moderate/high

low

unlikely

moderate

offer to screen negative patients, adjust for
symptomatic patients or screen positive
patients if it cannot be delayed

Vesico-amniotic shunting

low

moderate/high

low

unlikely

moderate

consider not offering screening

Fetal cystoscopy

unknown

moderate/high

low

unlikely

moderate

consider not offering screening

Laser for TTTS

high

low

low

unlikely

moderate

offer to screen asymptomatic patients; adjust
for symptomatic patients or screen positive
patients if it cannot be delayed

Selective feticide in
monochorionic twins

variable

low

low

Unlikely

moderate

offer to screen asymptomatic patients; adjust
for others

Tracheal occlusion for CDH

unknown

low

low

unlikely

moderate

consider not offering screening

Spina bifida closure

high

high

moderate/
high

low

high

delay if gestational age allows; if not, offer
only to screen negative patients if sufficient
local resources are available.

Rare conditions and procedures will need to be discussed on a case-by-case basis. Reproduced from Deprest et al. [1] and reprinted with permission.
TTTS, twin-to-twin transfusion syndrome; CDH, congenital diaphragmatic hernia.

longer shedding period has been described. Additionally
or alternatively – resources allowing – one could await 2
consecutive negative swabs.
For procedures requiring general endotracheal anesthesia (GA), which carries a higher risk of aerosolized viral transmission, one may need to be more restrictive.
Even asymptomatic patients operated upon electively in
the incubation period are at an increased risk [40].
For symptomatic SARS-CoV-2-positive women
(hence with COVID-19), it is preferable to delay fetal interventions whenever possible, firstly because COVID-19
symptoms of coughing and dyspnea may interfere with
surgery and secondly because surgical stress may trigger
COVID-19 deterioration or iatrogenic complications
[41]. A relevant example is prenatal spina bifida repair,
which is always performed under GA and carries an increased risk of postoperative respiratory problems, which
4
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could be mitigated by not using MgSO4. Delaying fetal
surgery, or even postponing repair until after birth, if it
cannot be done within the optimal gestational age window, seems more prudent. Fetal benefits seem to decrease
with advancing gestation; there is no evidence that prenatal spina bifida repair after 26 weeks improves outcomes
[42].
Life-Saving Fetal Therapies
Life-saving fetal therapies usually performed under local
anesthesia and conscious sedation should continue as maternal morbidity is low with this mode of anesthesia [41].
This includes fetoscopic placental laser ablation for twintwin transfusion syndrome. In twin-twin transfusion syndrome, postponing intervention may lead to fetal death,
preterm birth, or maternal complications, such as abrup
tion; amnioreduction will also facilitate maternal respiraDeprest et al.

tion. Fetal transfusions and shunting for fetal hydrops due
to pleural effusions or macrocystic lung lesions should likewise continue (Table 1). Investigational procedures or fetal
interventions of unproven benefit should not be performed.
Screening for SARS-CoV-2 prior to Fetal Therapy

Why Screen?
Routine presurgical screening for SARS-CoV-2 is only
relevant if a positive result can trigger interventions that
may improve maternal or fetal outcome or positively impact family members, other patients, or HCW. A positive
result might lead to patient isolation, delay or cancelation
of surgery, and/or use personal protective equipment
(PPE) by HCW. Asymptomatic patients who underwent
major elective surgery under GA, who, in retrospect, were
incubating COVID-19, all developed pneumonia; 44%
were admitted to an ICU and 20% died from acute respiratory distress syndrome [40]. Their mean age (55 years,
range 21–84) was not representative of pregnant women,
but surgery under GA during viral incubation poses a
higher risk of disease progression and complications than
in comparable controls [43]. For patients undergoing less
invasive surgery (including cesarean section), the risk was
lower (8%) but still much higher than normal [40].
Elective surgery in SARS-CoV-2-positive patients
should be avoided. Identification and isolation of SARSCoV-2-positive patients also prevents the introduction of
“super-spreaders” into hospitals, potentially infecting
many patients and HCW [44], especially if undergoing
aerosol generating procedures. Finally, there is the theoretical risk of vertical transmission during surgery in actively shedding patients.
How to Screen?
Screening strategies should be defined by local resource availability, result turnaround, and infection prevalence.
− Symptom questionnaires: screening for the most common COVID symptoms (cough, fever, dyspnea, nasal
obstruction, anosmia [45]) can be easily implemented.
Results are immediate, but false positives occur. This
also does not identify asymptomatic carriers (reported
in 6–14% of cases, depending on screening intensity)
[46] [Deprest, pers. commun.] and patients may underplay symptoms for fear of being denied care.
− Nasopharyngeal (NP) swabs: NP swabbing for RTPCR for SARS-Cov-2 RNA is currently the gold standard, being specific, but with a relatively high false
IFMSS Guidance on Fetal Diagnosis and
Therapy during the COVID-19 Pandemic

negative rate (due to inadequate sampling and rapid
decline in viral load just prior to sampling) [47]. Negative results are also less relevant if delayed or if testing
facilities or swabs are limited [48].
− Blood screening: infection with SARS-CoV-2 generates a typical antibody response, i.e., IgM and Ig G development after 12 and 14 days, respectively [34, 47,
49, 50], so antibody testing may be less useful acutely
but could confirm a past infection. However, whether
the presence of antibody actually confers immunity in
COVID-19 is yet to be determined.
Who to Screen?
Based on current data, it seems logical to screen all patients entering a hospital (including women undergoing
fetal interventions) using, at least, symptom questionnaires. NP swabs may be useful given that positive results
would affect intra- and postoperative care. Screening by
questionnaire and NP swabs should be done in women
scheduled for major elective procedures, to minimize the
risk of operating during the incubation period. A pending
NP swab result should never delay any urgent surgery,
but clinical questionnaire screening and PPE use in such
cases is recommended.
We should consider whether to allow partner and visitor access to hospital if resources allow. Units may also
want to screen asymptomatic HCW to prevent transmission of SARS-CoV-2 to patients or colleagues but also to
prevent unnecessary HCW absences for symptoms attributable to allergies and other respiratory infections
[48]. Questionnaire screening, followed by NP swabs in
symptomatic HCW, is a possible strategy. Ultimately, antibody-specific serum screening could identify HCW
who are COVID-19 immune, thus enabling their recruitment to teams caring for SARS-CoV-2-positive patients.
Postnatal Work-Up and Care of Neonates with
Congenital Anomalies/Conditions during COVID-19

Resuscitation of a neonate born to a mother suspected
or proven SARS-CoV-2-infection poses a risk to the neonate and HCW. The risks and benefits of delayed cord
clamping, immediate separation of the infant versus skinto-skin contact, and breast feeding should be reviewed
with parents. Strict infection control measures during delivery, quarantine of infected mothers, and close monitoring of susceptible neonates are of paramount importance to reduce the risk of neonatal or HCW transmission.
Fetal Diagn Ther
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If a mother is SARS-CoV-2 positive, neonates should
be tested 24 h after birth. RT-PCR is the gold standard
and a positive RT-PCR on NP/oropharyngeal or rectal
swab is confirmatory [51]. RT-PCR accuracy can be affected by primer and probe differences. Depending on the
sensitivity and specificity, result confirmation 24 h later
is recommended.
ICU Care of a Neonate with SARS-CoV-2 Exposure

To date, there are no reports of neonates with congenital anomalies and concurrent COVID-19 infection. If
one exhibited respiratory symptoms, chest X-ray might
demonstrate the diffuse ground glass appearance, typical
in adults, but neonatal radiographic criteria have not yet
been established.
NICU infants should ideally be cared for within an isolette in a negative pressure room. Contact and droplet
precautions are recommended, unless the infant is undergoing aerosol-generating procedures, e.g. deep suctioning, noninvasive ventilation such as continuous positive
airway pressure, intubation/extubation, or mechanical
ventilation, which mandate airborne precautions and full
PPE. Given the common use of uncuffed tubes in neonates, both conventional and high-frequency ventilators
are associated with some risk of aerosol generation.
Currently, evidence for maternal-neonatal transmission is limited. However, an asymptomatic mother could
infect an infant during nursing and breast feeding. A routine face mask worn by the mother, next to hygienic measures, may help reduce such a risk.
Treatment of neonates with congenital anomalies or
conditions should proceed as resources permit. Whenever
possible, surgery should be delayed until COVID-19 testing
is negative. Conversely, if surgery must be undertaken in a
SARS-CoV-2-positive neonate or in a person under investigation, PPE must be used by the anesthetic, surgical, neonatal and nursing teams throughout. SARS-CoV-2 may be
transmitted through multiple routes [52, 53]. Laparoscopic
procedures lead to aerosolization and precautions include
the use of a completely closed system, including insufflator,
tubing, peritoneal cavity, and suction tubing with appropriate filters (viral dimensions are 0.06–0.14 µm) [54]. Desufflation should also occur in this closed system [52, 53].
The short-term outcome in SARS-CoV-2-positive neonates appears favourable, with most exhibiting only mild
symptoms. So far, no neonates have been reported to develop severe COVID-19 pneumonia or die as a result of this
illness [13, 31, 33, 55–57]. One reported seriously ill neonate
6
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was probably symptomatic from prematurity and bacterial
rather than viral infection [33]. Although no long-term developmental data on COVID-19-positive neonates exist
yet, it is reassuring that the virus is not as neurotropic as
other viruses. Pediatric COVID-19 infections seem to have
a milder course and a better prognosis than adult cases, and
deaths have been extremely rare. Fever and respiratory
symptoms predominate, with few developing severe pneumonia [51]. There is no evidence that immunoglobulins,
antivirals, or steroids improve outcomes.
Horizontal Transmission: Risks to HCW

SARS-CoV-2 poses a potentially serious risk to HCW
[10]. This has led to a demand for testing of all pregnant
women undergoing procedures, so that appropriate precautions can be taken if the screen is positive. With effective screening and testing in place, and appropriate PPE
use, the risk of HCW transmission is probably low [51,
58]. This may not hold true when complex fetal operations are performed – necessitating many teams working
in physical proximity, thus increasing the risk of exposure
of multiple HCW. Any fetal surgery requiring (aerosolgenerating) maternal intubation carries higher risks than
procedures done under local or regional anesthesia [51].
Nevertheless, regional anesthesia or conscious sedation
may require conversion to general anesthesia with intubation. Maternal NP testing should therefore be considered in any cases potentially requiring intubation.
The anesthesia team must wear appropriate PPE for
airborne, droplet, and contact infection prior to intubation and extubation. In addition, insertion of a high-efficiency particulate air filter on the endotracheal tube and
the use of in-line suctioning are important to reduce aerosolization [59–61]. If the surgical procedure is also aerosol generating, then all personnel in the operating room
must wear PPE. If endotracheal intubation for general anesthesia is the only aerosol-generating portion of the procedure, the surgical and nursing personnel can stay outside of the operating room during intubation. After waiting 20–30 min (depending on the rate of air exchange in
the room) to allow for evacuation of 99% of the aerosol
from the atmosphere [62], the surgical and nursing personnel can then enter the room wearing standard PPE.
The relative benefits of personnel protection need to be
contrasted with the risk of added anesthesia time. Postoperative recovery of SARS-CoV-2 patients in the operating room and direct transfer to an isolation room afterward also helps to limit the exposure to additional HCW.
Deprest et al.

Ethics in obstetrics provides us with a framework to
guide management of pregnant women with SARSCoV-2 infection. The principle of beneficence creates the
obligation to provide management that deliberative (i.e.,
evidence-based, rigorous, transparent, and accountable)
clinical judgment should result in a net clinical benefit.
The ethical principle of respect for autonomy obliges
caregivers to empower women to make informed decisions about their pregnancy care. This involves an informed consent process that provides information about
reasonable care options including their benefits and risks,
supporting her understanding and evaluation based on
her own values and belief [63].
In the informed consent process for invasive prenatal
diagnosis and interventions for fetal benefit there is no
autonomy-based ethical obligation to provide a SARSCoV-2-positive patient with information about theoreti-

cal risks. The informed consent process for clinical investigation or maternal-fetal intervention should provide information about risks, based on prior investigation with
animal and human subjects. A major purpose of clinical
investigation is to identify and document such risks. Normally, identification of theoretical outcomes is excluded
as a study objective and should not be included in the informed consent process. Moreover, discussion of theoretical benefits and risks can confuse or distract patients
and does not empower informed decision making.
− Invasive prenatal diagnosis: there is currently no documented additional risk of pregnancy loss or fetal or
maternal morbidity from invasive prenatal diagnosis
in SARS-CoV-2-positive pregnant women [13]. In informed consent, there is no autonomy-based ethical
obligation to provide information about undocumented additional risks of invasive procedures. It might reassure women who express concern to learn that there
are no documented additional risks.
− Maternal-fetal intervention for fetal benefit: there is no
documented additional risk of pregnancy loss, fetal
harm, maternal morbidity or mortality, or neonatal
harm from fetal interventions in SARS-CoV-2 positive
pregnant women [1, 2]. No studies have explored fetal
or neonatal risks. In informed consent, there is no autonomy-based ethical obligation to provide information about undocumented additional risks of fetal intervention. It might reassure women who express concern to learn that there are no documented additional
risks.
− Use of resources: in a public health emergency, there
is a beneficence-based ethical obligation of hospitals
and HCW to reduce mortality risks in the affected
population. To fulfil this obligation, hospitals may justifiably divert their material and human resources
away from nonessential services. There is, however, a
beneficence-based constraint: essential services such
as obstetrics must continue to have sufficient resources, especially to prevent maternal and perinatal mortality. It is consistent with this constraint to suspend
accepted maternal-fetal interventions that may not
impact on perinatal mortality. Clinical trials do not do
so; it is therefore consistent to suspend maternal-fetal
trials.
− Restrictions on termination of pregnancy (TOP):
where legally permitted, TOP is ethically justified
when, following informed consent, a woman chooses
TOP [4]. TOP is time sensitive and should never be
classified as “elective,” even during a public health
emergency [9, 3]. It follows that TOP restrictions, on
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Resource Perspective

This pandemic is stretching healthcare systems, ICU,
and PPE availability and it is stressing HCW. Many elective procedures have been cancelled and admissions for
non-life-threatening conditions have diminished. Given
this strain on resources, it is essential for each fetal treatment center to evaluate its own program and determine
which procedures can or cannot be offered during this
crisis, based on their local situation and available alternatives. It is perhaps logical to suspend fetal procedures of
a greater complexity, given their use of HCW, potential
need for ICU beds, and/or prolonged hospital admission
[41]. In contrast, life-saving fetal blood transfusions and
fetoscopic laser therapy for twin-twin transfusion syndrome can often be performed in outpatients or entailing
a brief hospital admission. For SARS-CoV-2-positive patients requiring urgent fetal therapy, when and where to
perform these procedures must be carefully considered.
The loss of key personnel due to illness or redeployment
may also adversely impact the ability to offer some fetal
interventions. COVID-19 screening and/or testing and
PPE use must be regularly reviewed and modified as fetal
therapy demands and available resources change. In areas
with multiple, perhaps even competing, fetal programs,
this may be the time to work together and consolidate
operations. In countries where national health systems
commission fetal procedures, mitigation plans for these
highly specialized services may be required.
Ethical Framework
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Table 2. Summary of recommendations

–

Routine antenatal care should be adjusted by spacing out appointments and using telemedicine and home-based care. US
and noninvasive prenatal screening may also need rearrangement.

–

If resources allow, there may be a place for generalized testing
of pregnant women for SARS-CoV-2 infection. We do recommend testing prior to any operative procedure.

–

Pregnant women with SARS-CoV-2 infection may have a variable disease severity. It is uncertain whether they are at increased
risk for COVID-19 disease. They should be managed based on
the severity and nature of their complications. Cesarean delivery
should be performed based on standard obstetric indications
and considered in cases of septic shock or acute organ failure.
Delivery may also facilitate maternal ventilation.

–

There is minimal and unconfirmed evidence for spontaneous
vertical transmission. This risk theoretically may be increased
by fetal procedures by disruption of either the feto-maternal
barrier or the fetal skin. One should avoid trans-placental instrument passage.

–

Fetal therapy is time sensitive and hence should not be considered as elective care. In SARS-CoV-2 positive patients, one
may consider delaying an intervention to avoid surgical morbidity, provided the procedure can wait. This applies, in particular, to complex procedures under general anesthesia and
in symptomatic patients. Conversely, life-saving minimally invasive procedures should continue.

–

Procedures of unproven fetal benefit should not be offered.

–

When caring for a neonate born to a mother with suspected
or confirmed COVID-19, strict infection control measures
should apply, including quarantine. Based on current data, the
spectrum of COVID-19 infection in neonates is usually mild,
and their short-term outcomes are favourable.

–

HCW incur a significant risk of SARS-CoV-2 infection, which
is an argument for testing patients. When caring for suspected
or SARS-CoV-2-positive patients, appropriate personal protective equipment should always be used.

–

The COVID-19 pandemic does not strike equally around the
world. Centers must periodically review and adjust their approach to fetal therapy as demands and available resources
change.

–

When consenting women with SARS-CoV-2 infection for fetal procedures of proven benefit, there is no autonomy-based
ethical obligation to provide information about theoretical
risks. Informed consent provides information about reasonable options and their benefits and risks, and supports patient
understanding and evaluation based on their own values and
beliefs.

–

TOP is time sensitive and should not be considered as “elective.”

–

Registration of maternal and fetal outcomes is recommended
because large cohort data will rapidly boost our knowledge.
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the grounds of being allegedly “elective” by governments [10], organizations, or payers, are ethically unjustified.
− Responsible management of the risk of horizontal
transmission: The professional virtue of self-sacrifice
creates the ethical obligation to take only reasonable
risks to one’s self and other HCW [1]. Current evidence
supports the deliberative clinical judgment that adherence to effective infection control measures reduces the
incidence of horizontal transmission to levels similar to
other infectious agents. To responsibly manage current
uncertainty, it is compatible with the professional virtue of self-sacrifice to exempt pregnant HCW, because
their future child cannot consent to exposure. It is also
compatible with self-sacrifice to exempt HCW whose
health or involvement in care provision may increase
the risk of horizontal transmission.
Research in the COVID-19 Era

Registers of maternal and fetal outcomes should be
supported to better understand this disease and to quantify pregnancy complications risks, such as miscarriage,
growth restriction, stillbirth, preterm delivery, and vertical transmission. Larger cohort data will accelerate and
improve our understanding, define appropriate measures
for screening, confinement, and management, and guide
disease prevention. This has been successful for other viral infections and it has rapidly boosted knowledge [64].
There is room for a coordinated approach to avoid interference or double registration [65–67], and data sharing
should be encouraged [68]. We strongly endorse registries to evaluate whether fetal interventions affect maternal or fetal outcomes.
Conclusion

COVID-19 has put enormous stress on patients, HCW
and healthcare systems. Nevertheless, fetal diagnosis and
pregnancy care must be maintained, and we must strive
to protect the vulnerable population of pregnant women
and their fetuses. Our recommendations are summarized
in Table 2. This includes both SARS-CoV-2-negative and
SARS-CoV-2-positive women with fetal anomalies or
conditions who may benefit from prenatal intervention.
Multidisciplinary case discussion should include available resources. HCW should discuss with parents the
risks and benefits of any procedure, including the possiDeprest et al.

bility of surgically induced morbidity. Ultimately, management decisions will depend on fetal and maternal condition and prevailing local circumstances.
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